BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26960712)

  • 1. Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany.
    Vetter L; Keller M; Bruckner T; Golatta M; Eismann S; Evers C; Dikow N; Sohn C; Heil J; Schott S
    Breast Cancer Res Treat; 2016 Apr; 156(2):289-99. PubMed ID: 26960712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk-adapted surveillance: focus on familial breast and ovarian cancer].
    Rhiem K; Schmutzler RK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):307-11. PubMed ID: 24562705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative.
    Brannon Traxler L; Martin ML; Kerber AS; Bellcross CA; Crane BE; Green V; Matthews R; Paris NM; Gabram SG
    Ann Surg Oncol; 2014 Oct; 21(10):3342-7. PubMed ID: 25047474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not.
    Vos J; Oosterwijk JC; Gomez-Garcia E; Menko FH; Collee MJ; van Asperen CJ; Jansen AM; Stiggelbout AM; Tibben A
    Patient Educ Couns; 2012 Feb; 86(2):239-51. PubMed ID: 21684708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics.
    Schott S; Vetter L; Keller M; Bruckner T; Golatta M; Eismann S; Dikow N; Evers C; Sohn C; Heil J
    Arch Gynecol Obstet; 2017 Jun; 295(6):1451-1458. PubMed ID: 28439664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
    Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
    Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
    Vos J; van Asperen CJ; Oosterwijk JC; Menko FH; Collee MJ; Gomez Garcia E; Tibben A
    Psychooncology; 2013 Apr; 22(4):902-10. PubMed ID: 22740372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18-30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial.
    Kwiatkowski F; Dessenne P; Laquet C; Daures JP; Gay-Bellile M; Bignon YJ
    Trials; 2016 Oct; 17(1):509. PubMed ID: 27769293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term experiences with genetic consultation in people with hereditary breast and ovarian cancer.
    Eismann S; Vetter L; Keller M; Bruckner T; Golatta M; Hennings A; Domschke C; Dikow N; Sohn C; Heil J; Schott S
    Arch Gynecol Obstet; 2016 Nov; 294(5):1011-1018. PubMed ID: 27282618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of intensified early cancer detection in high-risk patients with familial breast and ovarian cancer.
    Lux MP; Ackermann S; Nestle-Krämling C; Goecke TO; Niederacher D; Bodden-Heidrich R; Bender HG; Beckmann MW; Fasching PA
    Eur J Cancer Prev; 2005 Aug; 14(4):399-411. PubMed ID: 16030432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk.
    Kwiatkowski F; Arbre M; Bidet Y; Laquet C; Uhrhammer N; Bignon YJ
    PLoS One; 2015; 10(6):e0127363. PubMed ID: 26047126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial breast cancer: Genetic counseling over time, including patients´ expectations and initiators considering the Angelina Jolie effect.
    Evers C; Fischer C; Dikow N; Schott S
    PLoS One; 2017; 12(5):e0177893. PubMed ID: 28542378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.